Navigation Links
MO BIO Laboratories, Inc. launches new kits for fast DNA and RNA clean-up
Date:11/19/2013

CARLSBAD, Calif., Nov. 19, 2013 /PRNewswire/ -- MO BIO Laboratories, Inc., the leader in microbial, stool, plant, and soil nucleic acid purification, announces the launch of the PowerClean® Pro DNA and RNA Clean-Up Kits, featuring a fast, 7 minute protocol for removal of amplification inhibitors including humic substances, polysaccharides, polyphenolics, heme, and lipids from purified DNA or RNA.

(Photo: http://photos.prnewswire.com/prnh/20131119/LA19528)

The PowerClean® Pro DNA and RNA Clean-Up Kits are the latest products in MO BIO's Power line of kits which contain patented Inhibitor Removal Technology® (IRT). IRT eliminates inhibitory substances often contained in soil, water, stool, plants, seeds, biofilm and other sample types, resulting in pure nucleic acids that are ready to use in PCR, qPCR and next generation sequencing

Features of the PowerClean® Pro DNA and RNA Clean-Up Kits include:

  • Efficient secondary purification – Fast and easy 7 minute protocol to clean up your problematic DNA or RNA
  • Removes challenging impurities – Purifies nucleic acids containing humic substances, polyphenolics, polysaccharides and other amplification inhibitors
  • Successful amplification - High purity nucleic acids for use in PCR, qPCR and next generation sequencing

The PowerClean® Pro DNA and RNA Clean-Up Kits are available now. For more information, visit the MO BIO website (http://mobio.com/powerclean-pro) or call 800-606-6246.

MO BIO Laboratories, Inc. (www.mobio.com) has developed innovative tools for researchers in molecular biology since 1993. A global leader in solutions for soil and microbial nucleic acid purification, MO BIO's Power kits contain patented Inhibitor Removal Technology® for removal of PCR inhibiting substances during the nucleic acid purification procedure. For clinical samples, the BiOstic™ kits provide solutions for higher yields and purity of nucleic acids. At MO BIO Laboratories, Inc., our focus is quality products that work, save time and function for all sample types, not just the easy ones. It is MO BIO's aim to make researchers' working lives more productive and efficient, creating time to focus on what is critical, not just in work, but in life.


'/>"/>
SOURCE MO BIO Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IGI Laboratories, Inc. Announces Thirteenth ANDA Submission
2. IGI Laboratories, Inc. Receives Formal US FDA Approval For Site Transfer Of Econazole Nitrate
3. IGI Laboratories, Inc. Announces Twelfth ANDA Submission
4. MO BIO Laboratories, Inc. launches a new kit for isolation of viral nucleic acids from environmental samples
5. Global Vascular Stents Market 2012-2016 Report with Abbott Laboratories, Medtronic Inc. and Boston Scientific Corp. Dominating
6. Charleston Laboratories, Inc. Announces Successful Completion of Pre-IND Meeting on New Migraine Treatment CL-H1T
7. Clontech Laboratories, Inc. Partners With Rubicon Genomics To Increase Speed And Efficiency Of Sample Preparation For RNA Sequencing
8. Besins Healthcare, Shin Nippon Biomedical Laboratories, Ltd Announce Delivery Technology Licensing Agreement for Intranasal Progesterone
9. FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment
10. Antigen Laboratories, Inc. to be Acquired by Ares Life Sciences
11. Positive Data, Pipeline Improvements & Market Expansion - Research Report on Abbott Laboratories, Stryker Corporation, St. Jude Medical, Cardiovascular Systems and MAKO Surgical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CITY, Calif. , March 28, 2017 /PRNewswire/ ... company focused on the development and commercialization of ... pain, announced that the European Medicines Agency (EMA) ... sublingual tablet, 30 mcg) Marketing Authorisation Application (MAA) ... of the MAA is underway. The MAA for ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... , March 28, 2017 The ... reach USD 8.0 billion by 2025, according to a ... incidence of infectious diseases and cancer is expected to ... disease diagnosis over the coming years. In addition, higher ... autologous and allogenic stem cell therapy, due to adverse ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... ... For many women, getting birth control isn’t as easy as it should be. In fact, ... to a health care facility or a pharmacy within 60 minutes of where they live. ... for many who are faced with health or personal issues that leave them homebound. To ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... to be invited to the Siemens Healthineers annual customer education symposium, a world-class ... will take place from March 27 - 31, 2017 at the Atlanta Marriott ...
(Date:3/28/2017)... ... ... Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts of the world, is ... about journey and research recently on a blog and discussed some major aspects of ... deal with thyroid disease. , Dr. Wentz completed her graduation from the Midwestern ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... medical society dedicated to advancing the science and clinical practice of radiosurgery, ... RSSearch Patient Registry, a multi-institutional, observational registry established to standardize data collection ...
(Date:3/28/2017)... ... 28, 2017 , ... Z-Medica, LLC, a leading developer and ... (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 ... efforts by the American College of Surgeons, U.S. Department of Defense, Department of ...
Breaking Medicine News(10 mins):